C-UPILTreefrog Therapeutics
iPS-derived cell therapies, C-Stem, 3D microtissue
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-UPIL
C-UPILC-UPILiPS-derived cell therapies, C-Stem, 3D microtissue
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Treefrog Therapeutics iPS-derived cell therapies, C-Stem, 3D microtissue
TreeFrog Therapeutics is a Research & Development biotech advancing a pipeline of regenerative medicine cell therapies. Its lead program is in Parkinson’s Disease and is described as on track for a first-in-human trial by 2026. The company’s proprietary C-Stem technology is a biomimetic platform integrating GMP-compliant encapsulation to support large-scale cell production.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Treefrog Therapeutics — Early mechanism · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic